[go: up one dir, main page]

PE20181352A1 - Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias - Google Patents

Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias

Info

Publication number
PE20181352A1
PE20181352A1 PE2018000402A PE2018000402A PE20181352A1 PE 20181352 A1 PE20181352 A1 PE 20181352A1 PE 2018000402 A PE2018000402 A PE 2018000402A PE 2018000402 A PE2018000402 A PE 2018000402A PE 20181352 A1 PE20181352 A1 PE 20181352A1
Authority
PE
Peru
Prior art keywords
compounds containing
heterocyclic compounds
useful compositions
mycobacterial infection
compositions against
Prior art date
Application number
PE2018000402A
Other languages
English (en)
Inventor
Marvin J Miller
Garrett Moraski
Original Assignee
Marvin J Miller
Garrett Moraski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marvin J Miller, Garrett Moraski filed Critical Marvin J Miller
Publication of PE20181352A1 publication Critical patent/PE20181352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta referido a compuestos de Formulas I y II, en donde cada X es N, C-R3 o C-R4, con la condicion de que no mas de dos X sean N; R1 y R2 son independientemente hidrogeno, grupo acilo, grupo alquenilo, grupo alcoxi, entre otros; tambien se refiere a una composicion farmaceutica que los comprenden y a un metodo para elaborarlos. Dichos compuestos son utiles como agentes eficaces contra infecciones por micobacterias
PE2018000402A 2015-09-17 2016-09-19 Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias PE20181352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562220192P 2015-09-17 2015-09-17

Publications (1)

Publication Number Publication Date
PE20181352A1 true PE20181352A1 (es) 2018-08-22

Family

ID=58289763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000402A PE20181352A1 (es) 2015-09-17 2016-09-19 Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias

Country Status (14)

Country Link
US (2) US10919888B2 (es)
EP (1) EP3328382A4 (es)
JP (1) JP7055378B2 (es)
KR (1) KR20180053386A (es)
CN (1) CN108348510B (es)
AU (2) AU2016324598A1 (es)
BR (1) BR112018005208B1 (es)
CA (1) CA2998375A1 (es)
CL (1) CL2018000688A1 (es)
IL (1) IL257743B (es)
MX (2) MX386078B (es)
PE (1) PE20181352A1 (es)
WO (1) WO2017049321A1 (es)
ZA (1) ZA201802323B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
MA49013A (fr) 2017-03-23 2021-05-05 Jacobio Pharmaceuticals Co Ltd Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020128981A1 (en) * 2018-12-21 2020-06-25 University Of Notre Dame Du Lac Discovery of bd oxidase inhibitors for the treatment of mycobacterial diseases
US20220235047A1 (en) * 2019-05-28 2022-07-28 Shionogi & Co., Ltd. A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
TWI861208B (zh) * 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
EP4028399B1 (en) * 2019-09-13 2024-02-14 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2022549881A (ja) * 2019-09-26 2022-11-29 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
WO2022194803A1 (en) * 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024206357A1 (en) * 2023-03-29 2024-10-03 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525602A1 (fr) 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
JPH0539205A (ja) 1990-12-21 1993-02-19 Takeda Chem Ind Ltd 農園芸用混合組成物
JP3026845B2 (ja) 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5464843A (en) 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
AU2223495A (en) 1994-04-15 1995-11-10 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
WO1996002542A1 (en) 1994-07-15 1996-02-01 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JPH09249666A (ja) 1996-01-12 1997-09-22 Takeda Chem Ind Ltd 三環性化合物の製造法およびその中間体
AU8096798A (en) 1997-06-27 1999-01-19 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
AUPP278498A0 (en) 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MX228790B (es) 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
CN1308327C (zh) 2000-04-27 2007-04-04 安斯泰来制药有限公司 咪唑并吡啶衍生物
US6552037B2 (en) 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US20050113576A1 (en) 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1699780A1 (en) 2003-12-23 2006-09-13 Pfizer, Inc. Novel quinoline derivatives
EP1748048A4 (en) 2004-05-10 2010-05-26 Banyu Pharma Co Ltd imidazopyridine
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
DE502005003491D1 (de) 2004-08-02 2008-05-08 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
DK1814880T3 (da) 2004-11-11 2009-05-18 Ferrer Int Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
DE102005016547A1 (de) * 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20080318999A1 (en) 2005-08-05 2008-12-25 Methvin Isaac Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
AU2007254361A1 (en) 2006-05-18 2007-11-29 Merck Sharp & Dohme Corp. Substituted esters as Cannabinoid-1 receptor modulators
DE602007009284D1 (de) 2006-09-29 2010-10-28 Actelion Pharmaceuticals Ltd 3-aza-bicycloä3.1.0ühexanderivate
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
EP2112880A4 (en) 2006-12-14 2011-12-21 Merck Sharp & Dohme ACYLBIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT METHOD
CN101631786A (zh) 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
AU2008223351A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
TW200901969A (en) 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
EP2200440B1 (en) 2007-07-23 2017-07-19 Crestone, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2715069C (en) 2008-02-01 2016-06-07 Orchid Research Laboratories Limited Novel heterocycles
EP2300470A2 (en) 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
US9066951B2 (en) 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012510983A (ja) 2008-12-04 2012-05-17 プロキシマジェン エルティーディー イミダゾピリジン化合物
EP2398796A4 (en) 2009-02-23 2012-10-10 Merck Canada Inc HETEROCYCLIC DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE
EP2401275B1 (en) 2009-02-24 2013-07-24 Respiratorius AB Naphthyridine derivatives having bronchodilating activity
PH12012500382A1 (en) 2009-09-03 2012-10-22 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN102762556B (zh) 2009-11-05 2017-04-26 圣母大学 咪唑并[1,2‑a]吡啶类化合物及其合成及使用方法
NZ602311A (en) 2010-03-18 2014-08-29 Pasteur Institut Korea Anti-infective compounds
MX345656B (es) 2011-02-25 2017-02-08 Janssen Pharmaceutica Nv (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
MX2013014082A (es) * 2011-05-30 2014-03-21 Astellas Pharma Inc Compuestos de imidazopiridina.
CA2855019A1 (en) * 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
AU2013292529A1 (en) 2012-07-18 2015-02-12 Marvin J. Miller 5,5-heteroaromatic anti-infective compounds
MX377581B (es) 2012-11-20 2025-03-10 Merial Inc Compuestos antihelmínticos y composiciones y método de uso de los mismos.
EP2927231B1 (en) * 2012-11-30 2017-09-20 Astellas Pharma Inc. Imidazopyridine compounds
HUE056198T2 (hu) * 2013-08-02 2022-02-28 Pasteur Institut Korea Fertõzés elleni vegyületek
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
CN109415349A (zh) 2016-06-16 2019-03-01 爱尔兰詹森科学公司 杂环化合物作为抗细菌剂
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP3266454A1 (en) 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Acc inhibitors for use in treating mycobacterial diseases
EA201991997A1 (ru) 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани Комбинированная терапия
CN108159049B (zh) 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
WO2019175737A1 (en) 2018-03-12 2019-09-19 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN108358917B (zh) 2018-04-24 2020-06-19 北京市结核病胸部肿瘤研究所 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
EP4028399B1 (en) 2019-09-13 2024-02-14 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Also Published As

Publication number Publication date
JP2018532723A (ja) 2018-11-08
ZA201802323B (en) 2019-01-30
AU2021203931A1 (en) 2021-07-08
RU2018111768A3 (es) 2020-02-20
HK1252225A1 (zh) 2019-05-24
MX2018003294A (es) 2019-04-25
CA2998375A1 (en) 2017-03-23
EP3328382A1 (en) 2018-06-06
IL257743A (en) 2018-04-30
CL2018000688A1 (es) 2018-11-16
MX386078B (es) 2025-03-18
MX2021000189A (es) 2021-03-25
JP7055378B2 (ja) 2022-04-18
CN108348510B (zh) 2022-01-04
AU2016324598A1 (en) 2018-03-15
KR20180053386A (ko) 2018-05-21
BR112018005208B1 (pt) 2023-12-12
EP3328382A4 (en) 2018-12-19
WO2017049321A1 (en) 2017-03-23
US10919888B2 (en) 2021-02-16
RU2018111768A (ru) 2019-10-17
US11820767B2 (en) 2023-11-21
CN108348510A (zh) 2018-07-31
US20180265506A1 (en) 2018-09-20
US20210198254A1 (en) 2021-07-01
BR112018005208A2 (pt) 2018-10-02
IL257743B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
PE20181352A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
PE20191552A1 (es) Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3)
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
MX386927B (es) Composicion y metodo para el crecimiento del cabello.
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
MX2018009645A (es) Derivados haloalilamina indol y azaindol como inhibidores de lisil-oxidasas y sus usos.
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
UY36651A (es) Compuestos antiestrogénicos
CO2018001628A2 (es) Composiciones y formulaciones antimicrobianas
MX378386B (es) Composiciones antiirritantes sinérgicas de taurina y aloe.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
DOP2016000253A (es) Nuevos compuestos
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
PE20160801A1 (es) Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
MX2018010209A (es) Proceso para preparar un elastomero de silicon con ingredientes activos hidrofilicos y una composicion para el cuidado personal que contiene el elastomero.